Using cellular in vitro models of glioblastoma and other solid tumors, we evaluated in our study the activity of a novel bispecific antibody termed NKAB-EGFR, which employs the binding domain of the EGFR-specific antibody cetuximab for tumor targeting and an NKG2D-interacting antibody fragment for NK-cell recruitment [36,37]. This evidence concerns the gene KLRK1 and glioblastoma.